Incidence of antiretroviral drug-related problems in the treatment of HIV among hospitalized patients in the Hospital Santa Clara, Bogotá
Abstract
Introduction: The antiretroviral therapy for the treatment of the human immunodeficiency virus (HIV) is a therapeutic strategy linked to drug-related problems that cause or can cause the appearance of negative results associated with the medication. It is important, therefore, to identify their incidence, characterize them, and classify them to design strategies to minimize their impact.
Objective: To estimate the overall incidence and the incidence of each one of the antiretroviral drugs-related problems in the treatment of the HIV infection in a cohort of hospitalized patients in Bogotá, Colombia.
Materials and methods: We conducted a descriptive, retrospective cohort study in patients aged 18 years or more diagnosed with HIV infection and under antiretroviral treatment hospitalized between January 1st, 2015, and December 31st, 2016, in the Hospital Santa Clara, Bogotá.
Results: The overall incidence of antiretroviral drug-related problems was 0.90 (95% CI: 0.85-0.93). The incidence of drug-drug interactions was 0.85 (95% CI: 0.80-0.90), 0.28 (95% CI: 0.22-0.35) for adverse reactions, and 0.12 (CI 95%: 0.08-0.17) for prescription errors.
Conclusion: Drug-related problems should be studied, diagnosed, prevented, and treated. Their knowledge can enable health care professionals to anticipate their emergence, reduce their incidence, implement risk management plans, and optimize adherence to antiretroviral treatment.
Downloads
References
Vella S, Schwartländer B, Sow SP, Eholie SP, Murphy RL. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;26:1231-41. https://doi.org/10.1097/QAD.0b013e32835521a3
World Health Organization. Data and statistics. Geneva: WHO; 2017. Fecha de consulta: 2 de septiembre de 2018. Disponible en: https://www.who.int/healthinfo/statistics/en/
World Health Organization. Summary of the global HIV Epidemic 2017. Fecha de consulta: 12 de noviembre de 2018. Disponible en: https://www.hiv.gov/federal-response/pepfarglobal-aids/global-hiv-aids-overview
Pau AK, George JM. Antiretroviral therapy: Current drugs. Infect Dis Clin North Am. 2014;28:371-402. https://doi.org/10.1016/j.idc.2014.06.001
Tsibris AM, Hirsch MS. Tratamiento antirretroviral de la infección por el virus de la inmunodeficiencia humana. En: Bennett, Dolin y Blaser editores. Enfermedades infecciosas. Principios y práctica. 2016; p. 1704-24.
Comité de Consenso de la Universidad de Granada. Tercer consenso de Granada sobre problemas relacionados con medicamentos y resultados negativos asociados a la medicación. Ars Pharm. 2007;48:5-17.
Red-PARF. Buenas prácticas de farmacovigilancia para las Américas. Washington: Red Panamericana de Armonización de la Reglamentación Farmacéutica, Red PARF; 2010. p. 78.
Serrano-López De Las Hazas JI. Interacciones farmacológicas de los nuevos antirretrovirales. Farm Hosp. 2011;35:36-43. http://doi.org/10.1016/j.farma.2010.01.018
Li EH, Foisy MM. Antiretroviral and medication errors in hospitalized HIV-positive patients. Ann Pharmacother. 2014;48:998-1010. http://doi.org/10.1177/1060028014534195
Méndez-Arévalo HA. Compromisos del Convenio 1282 de 2015. Fecha de consulta: 20 de octubre de 2018. Disponible en: http://www.saludcapital.gov.co/BibliotecaPSFFaspx/Convenios de Especialización/Hospital Santa Clara/Convenio 1282-2015/Propuesta de Fortalecimiento CV 1282-2015 31082015.pdf
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, D.C.: Department of Health and Human Services; 2015.
Doherty MJ. Algorithms for assessing the probability of an adverse drug reaction. Respir Med CME. 2009;2:63-7. https://doi.org/10.1016/j.rmedc.2009.01.004
Behera SK, Das S, Xavier AS, Velupula S, Sandhiya S. Comparison of different methods for causality assessment of adverse drug reactions. Int J Clin Pharm. 2018;40:903-10. https://doi.org/10.1007/s11096-018-0694-9
Belhekar MN, Taur SR, Munshi RP. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol. 2014;46:117-20. https://doi.org/10.4103/0253-7613.125192
Ministerio de Salud y Protección Social. Guía de práctica clínica basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años de edad o más) y adultos. Bogotá, D.C.; Minprotección; 2014.
Federal Drug Administration. What is a serious adverse event?; 2016. Fecha de consulta: 12 de noviembre de 2018. Disponible en: https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm
Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013;28:1302-10. https://doi.org/10.1007/s11606-013-2449-6
Astuvilca J, Arce-Villavicencio Y, Sotelo R, Quispe J, Guillén R, Peralta L, et al. Incidencia y factores asociados con las reacciones adversas del tratamiento antirretroviral inicial en pacientes con VIH. Rev Peru Med Exp Salud Pública. 2007;24:218-24.
Bezabhe WM, Bereznicki LR, Chalmers L, Gee P, Kassie DM, Bimirew MA, et al. Adverse drug reactions and clinical outcomes in patients initiated on antiretroviral therapy: A prospective cohort study from Ethiopia. Drug Saf. 2015;38:629-39. https://doi.org/10.1007/s40264-015-0295-7
Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reactions to antiretroviral therapy (ARVs): Incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12:1-25. https://doi.org/10.1186/1472-6904-12-7
World Health Organization. International drug monitoring: The role of national centres. Tech Rep Ser. 1972. Fecha de consulta: 12 de noviembre de 2018. Disponible en: http://apps. who.int/iris/handle/10665/40968
Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356:1255-9. https://doi.org/10.1016/S0140-6736(00)02799-9
Mok S, Minson Q. Drug-related problems in hospitalized patients with HIV infection. Am J Heal Pharm. 2008;65:55-9. https://doi.org/10.2146/ajhp070011
Rastegar DA, Knight AM, Monolakis JS. Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis. 2006;43:933-8. https://doi.org/10.1086/507538
Pastakia SD, Corbett AH, Raasch RH, Napravnik S, Correll TA. Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. Annals of Pharmacotherapy. 2008;42:491–497. https://doi.org/10.1345/aph.1K547
Rehan HS, Chopra D, Kakkar AK. Physician’s guide to pharmacovigilance: Terminology and causality assessment. Eur J Intern Med. 2009;20:3-8. https://doi.org/10.1016/j.ejim.2008.04.019
Machado J, Morales C, Hoyos V. Frecuencia de potenciales interacciones medicamentosas entre antirretrovirales y otros grupos farmacológicos en pacientes colombianos. Rev Investig Andin. 2014;16:910-20.
Some similar items:
- Mauricio Beltrán, María Cristina Navas, María Patricia Arbeláez, Jorge Donado, Sergio Jaramillo, Fernando De la Hoz, Cecilia Estrada, Lucía del Pilar Cortés, Amalia de Maldonado, Gloria Rey, Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in Colombia , Biomedica: Vol. 29 No. 2 (2009)
- María Patricia Arbeláez, Alexánder Arbeláez, Rubén Darío Gómez, Carlos Rojas, Lázaro Vélez, Sonia Luz Arias, Jorge Nagles, Luz Marina Peláez, Gloria Betancourt, Gloria Velásquez, Effectiveness of prophylaxis against tuberculosis in patients infected with HIV , Biomedica: Vol. 27 No. 4 (2007)
- María Teresa Rugeles, Paula A. Velilla, Carlos J. Montoya, Mechanisms of human natural resistance to HIV: A summary of ten years of research in the Colombian population , Biomedica: Vol. 31 No. 2 (2011)
- Jaiberth Cardona-Arias, Luz Peláez-Vanegas, Juan López-Saldarriaga, Marcela Duque-Molina, Oscar Leal-Álvarez, Health related quality of life in adults with HIV/AIDS in Colombia , Biomedica: Vol. 31 No. 4 (2011)
- Arletta Añez, Marco Fidel Suárez, Jorge Cuba, Factors that delay malaria diagnosis and treatment in the municipality of Riberalta in Bolivia , Biomedica: Vol. 32 (2012): Suplemento 1, Malaria
- Andrés F. Henao-Martínez, Guido R. González-Fontal, Steven Johnson, A case of community-acquired Acinetobacter junii-johnsonii cellulitis , Biomedica: Vol. 32 No. 2 (2012)
- Omar Segura, Carlos Maldonado, Evaluation of medication side-effects from an economic perspective. , Biomedica: Vol. 23 No. 4 (2003)
- Sandra Rincón, Adriana Celis, Leticia Sopó, Adriana Motta, María Caridad Cepero de García, Malassezia yeast species isolated from patients with dermatologic lesions. , Biomedica: Vol. 25 No. 2 (2005)
- Adriana M. Celis, María Caridad Cepero de García, Genetic polymorphism of Malassezia spp. yeast isolates from individuals with and without dermatological lesions. , Biomedica: Vol. 25 No. 4 (2005)
- Zulbey Rivero-Rodríguez, Amparo Hernández, Ángela Bracho, Solneumar Salazar, Rafael Villalobos, Prevalence of intestinal microsporidia and other intestinal parasites in HIV positive patients of Maracaibo, Venezuela , Biomedica: Vol. 33 No. 4 (2013)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
